Taking advantage of a previously reported genetic signature of atopic dermatitis (AD) in patients who responded to anti-IL-22 (fezakinumab, FZ), they searched for such transcriptomic signatures in adults with severe asthma to determine whether they could be successfully treated with this biological. Here, IL22 is linked to asthma.